Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06332092
Title FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Acronym HNSCC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fulgent Pharma LLC.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.